Search

Tobey J Macdonald

from Decatur, GA
Age ~60

Tobey Macdonald Phones & Addresses

  • 631 S Mcdonough St, Decatur, GA 30030
  • Chevy Chase, MD
  • 3000 Connecticut Ave NW, Washington, DC 20008
  • Elk Grove, CA
  • Milton, MA
  • New York, NY
  • 616 Mckoy St, Decatur, GA 30030

Work

Company: Aflac Cancer/Blood Disorder Ctr Address: 5455 Meridian Marks Rd Ne Suite 400, Atlanta, GA 30342 Phones: (404) 785-3240

Education

School / High School: Weill Cornell Medical College 1991

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatric Oncology & Pediatric Hematology, 2007

Specialities

Pediatric Hematology & Oncology

Professional Records

Medicine Doctors

Tobey Macdonald Photo 1

Dr. Tobey J Macdonald, Atlanta GA - MD (Doctor of Medicine)

View page
Specialties:
Pediatric Hematology & Oncology
Address:
Aflac Cancer/Blood Disorder Ctr
5455 Meridian Marks Rd Ne Suite 400, Atlanta, GA 30342
(404) 785-3240 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2007
Pediatrics, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Weill Cornell Medical College
Graduated: 1991
Medical School
Children's Hospital Los Angeles
Graduated: 1991
Tobey Macdonald Photo 2

Tobey Macdonald

View page
Specialties:
Pediatric Hematology-Oncology
Work:
Aflac Cancer Center & Blood Disorder Center
5455 Meridian Marks Rd STE 400, Atlanta, GA 30342
(404) 785-3240 (phone), (404) 785-3600 (fax)
Education:
Medical School
Cornell University Weill Medical College
Graduated: 1991
Conditions:
Leukemia
Sickle-Cell Disease
Anemia
Hemolytic Anemia
Hodgkin's Lymphoma
Languages:
English
Spanish
Description:
Dr. Macdonald graduated from the Cornell University Weill Medical College in 1991. He works in Atlanta, GA and specializes in Pediatric Hematology-Oncology. Dr. Macdonald is affiliated with Childrens Heathcare Of Atlanta At Scottish Rite.
Tobey Macdonald Photo 3

Tobey J Macdonald, Washington DC

View page
Specialties:
Pediatric Hematologist / Oncologist
Address:
111 Michigan Ave Nw, Washington, DC 20010
Education:
Cornell University, Weill Cornell Medical College - Doctor of Medicine
Childrens Hospital Los Angeles - Fellowship - Pediatric Hematology/Oncology (Pediatrics)
Board certifications:
American Board of Pediatrics Certification in Pediatrics
American Board of Pediatrics Sub-certificate in Pediatric Hematology/Oncology (Pediatrics)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Tobey John Macdonald
Tobey Macdonald MD
Pediatric Oncologist · Pediatrician
111 Michigan Ave NW, Washington, DC 20010
(202) 476-2800

Publications

Us Patents

Gene Expression Based Method For Distinguishing Metastatic From Non-Metastatic Forms Of A Tumor, And Use In Designing Therapeutic Drugs

View page
US Patent:
20040126755, Jul 1, 2004
Filed:
Aug 29, 2001
Appl. No.:
09/940454
Inventors:
Dietrich Stephan - Falls Church VA, US
Tobey MacDonald - Washington DC, US
Kevin Brown - Washington DC, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
Gene expression profiling of tumors, clinically designated as either metastatic (M+) or non-metastatic (M0), identifies genes whose expression differed significantly between classes. A class-prediction algorithm based on these medulloblastoma genes assigned the sample class to these tumors (M+ or M0) with 72% accuracy and to four additional independent tumors with a 100% accuracy. Class prediction also assigned the metastatic medulloblastoma cell line Daoy to the metastatic class. Notably upregulated in the M+ tumors were platelet derived growth factor receptor alpha (PDGFRA) and members of the downstream RAS/mitogen-activated protein kinase (MAPK) signal transduction pathway. Immunohistochemical validation on an independent set of tumors showed significant overexpression of PDGFRA in M+ tumors as compared to M0 tumors. In in vitro assays, PDGFA enhanced medulloblastoma migration and increased downstream MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK1 (p42 MAPK), and MAPK3 (p44 MAPK) phosphorylation in a dose-dependent manner. Neutralizing antibodies to PDGFRA or U0126, a highly specific chemical inhibitor of MAP2K1 and MAP2K2 known as U0126, blocked MAP2K1, MAP2K2, and MAPK1/3 phosphorylation, inhibited migration, and prevented PDGFA-stimulated migration. These results provide the first insight into the genetic regulation of medulloblastoma metastasis and are the first to suggest a role for and the RAS/MAPK signaling pathway in medulloblastoma metastasis. Inhibitors of PDGFRA and RAS proteins, among others overexpressed M+ genes identified herein, represent novel therapeutic targets in medulloblastomas and other M+/MO tumors. The inventive method of prediction and targeted therapy is applicable to any tumor that exists in both M+ and MO forms, such as the neurotumors glioma, neuroblastoma and ependymoma, as well as lung and breast cancers.
Tobey J Macdonald from Decatur, GA, age ~60 Get Report